Ozempic for All?

Drugs like Ozempic and Zepbound have revolutionized weight loss. And starting next year, the drugs are going to become more affordable for Americans because of a deal struck with pharmaceutical companies by the Trump administration.

Eshe Nelson, who covers economics and business news, explains how the change has its origins in a huge business blunder from the creator of Ozempic, Novo Nordisk.

Guest: Eshe Nelson, a reporter for The New York Times based in London, where she covers economics and business news.

Background reading: 

• How Ozempic’s maker lost its shine after creating a wonder drug.
• What Trump’s new drug pricing deal means for people with obesity.

Photo: Sergei Gapon/Agence France-Presse — Getty Images

For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday. 

Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Thank you for listening to this episode of Daily News. We've gathered all the additional resources, book For more updates and exclusive content, visit our official site: ➡️ 🚨[VIP ACCESS]🚨

Subscribe and leave a review! ➡️ SUBSCRIBE

Copyright Disclaimer: We are not the official Daily news or Spotify feed. All rights to the original content belong to their respective owners. This channel is sustained through dynamic ad insertion to offset AI processing, hosting, and transcription costs.

---

Hosted on Acast. See acast.com/privacy for more information.